In the longest study yet, melanoma patients given the personalised vaccine alongside the immunotherapy drug Keytruda were half more likely to be alive three years later.
In the longest study yet, melanoma patients given the personalised vaccine alongside the immunotherapy drug Keytruda were half more likely to be alive three years later.
Genentech sponsored a health equity symposium in partnership with the American Cancer Society and the University of Illinois Cancer Center over the weekend to underscore the need for health equity.